� ViRexx Medical Corp. (TSX:VIR) (AMEX:REX) ("ViRexx"), a company focused on developing innovative-targeted therapeutic products that offer wagerer quality of life and a renewed hope for living. Its platform technologies include product candidates for the intervention of Hepatitis B, Hepatitis C, avian influenza viral infections, biological defense and nanoparticle applications, select solid tumors and late-stage ovarian cancer, announced that further to its press release of July 16, 2008, ViRexx has received a final receipt from the Alberta Securities Commission and conditional approval from The Toronto Stock Exchange with regard to a rights offering by way of a Short Form Prospectus dated July 17, 2008 ("Final Prospectus"). A Form F-7, Registration Statement Under the Securities Act of 1933, has too been filed with the Securities and Exchange Commission.
The Final Prospectus was mailed to registered shareholders of ViRexx on July 30, 2008 together with the rights certificates.
Notice to Reader:
This
